ВЛИЯНИЕ АМЛОДИПИНА НА АРТЕРИАЛЬНОЕ ДАВЛЕНИЕ, ЭНДОТЕЛИАЛЬНУЮ ФУНКЦИЮ, БРОНХИАЛЬНУЮ ПРОХОДИМОСТЬ И КАЧЕСТВО ЖИЗНИ У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ И ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНЬЮ ЛЕГКИХ

1. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.//J. Hypertension 2003; 21: 1011-1053.

2. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Всероссийское научное общество кардиологов. Секция артериальной гипертонии. Москва, 2004, 20 с.

3. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Barden of Disease Study//Lancet. 1997; 349: P. 1498-1504.

4. Stewart A.L., Greenfield S., Hays R.D., et al Functional status and wellbeing of patients with chronic conditions: results from the Medical Outcomes Study//JAMA 1989;262,907-913

5. Decalmer P.B.G., Chatterjee S.S., Cruikshank J.M. et al. Я-Blockers and asthma//Br. Heart. J. 1978;40,184-189

6. Lawrence D.S., Sahay J.N., Chatterjee S.S., et al. Я-Blockers in asthma.//Drugs 1983;25,232-236

7. Goldszer R.C., Lilly L.S., Solomon H.S. Prevalence of cough during angiotensin converting enzyme inhibitor therapy//Am. J. Med. 1988;85,887

8. Simon S.R., Black H.R., Moser M., et al. Cough and ACE inhibitors//Arch. Intern. Med. 1992;152,1698-1700

9. Barnes P.J., Wilson N.M., Brown M.J. A calcium antagonist, nifedipine, modifies exercise-induced asthma//Thorax 1981;36,726-730

10. Williams D.O., Barnes P.J., Vickers H.P., et al. Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma//BMJ 1981;282,348

11. Ballester E., Roca J., Rodriguez-Roisin R. et al. Effect of nifedipine on arterial hypoxemia occurring after methacholine challenge in asthma//Thorax. 1986;41,468-472

12. Buington R.P., Chen J., Furberg C.D. et al. Effect of amlodipine on cardiovascular events and procedures//J. Am. Coll. Cardiol., 1999; 31: SupplA: P. 314A.

13. Задионченко B.C.. Применение пролонгированных антагонистов кальция у больных артериальной гипертонией при ХОБЛ. В кн.: Артериальная гипертония при хронической обструктивной болезни легких. М., Анахарсис, 2005, С. 93-106.

14. Lin M., Yang Y.F., Lee D. et al. Comparisons of long-term effects of lisinopril vs nifedipine vs conventional therapy in the treatment of mild-to-moderate hypertension in patients with chronic obstructive pulmonary disease//Chinese. Med. J. 1996;57,392-400

15. Dart R.A., Gollub S., Lazar J., et al. Treatment of Systemic Hypertension in Patients Wth Pulmonary Disease: COPD and Asthma//Chest. 2003;123: 222-243.

16. Fratolla A., Parati G., Guspidi C. et al. Prognostic value of 24-hour pressure variability. // J Hypertens. - 1993. - №11. - P. 1133-1137.

17. Berkels R., Egink G., Marsen Т.А. et al. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms.//Hypertens., 2001, №37 (2), P. 240-245.

18. Zhang X., Hintze T.H. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of calcium-channel blocking agent//Circulation 1998; 97: 576-80.

19. Ding Y., Vaziri N.D. Nifedipine and Diltiazem but Not Verapamil Up-Regulate Endothelial Nitric-Oxide Synthase Expression//J. Pharmacol. Exp. Ther. 2000; 292: 606-9.